ArticleMolecular biology reports2026
Adapalene inhibits the activity of CD44, a cancer stem cell biomarker in Triple negative breast cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the JAK/STAT signalling axis in cancer: chemopreventive potential of natural compounds with emerging focus on retinoids.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Mechanisms of Paclitaxel Resistance: Recent Advances and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOne of the crucial steps in the development of tumor metastasis is tumor cell invasion. This stage initiates a sequence of molecular interactions that enable invasive cells to adhere to the extracellular matrix (ECM) through the activity of cell adhesion molecules (CAMs). The primary cell surface receptor for ECM components is CD44. High levels of CD44 are necessary for breast cancer stem cells (BCSCs) to retain the multipotency of the BCSC population.
aimThis study examines methods for focusing on tumour cells that overexpress CD44 and provides a thorough summary of CD44's function in the development of breast cancer.
methodsUsing in vitro models, we evaluated the therapeutic potential of Adapalene, a repurposed drug that is often used to treat acne. Western blotting analysis was used to check the expression of resistance markers in Paclitaxel-resistant cells. The ability of Adapalene to target and exhibit CD44 expression was examined using immunocytochemistry methods. Additionally, we used an in silico/docking technique to assess Adapalene's interaction with CD44.
resultsAccording to our findings, Adapalene selectively kills TNBC cells rather than non-TNBC cells, particularly in the 4T1 model. Interestingly, drug-resistant produced MDA-MB-231 cells exhibited a 298-fold increase in ic50 value in comparison to the parental MDA-MB-231 cells. The findings showed that Adapalene targets CD44, a crucial stemness biomarker, to decrease the stemness traits of drug-resistant cells.
conclusionOverall, this study highlights how CD44 overexpression accelerates the growth of breast cancer and transforms drug-resistant cells into stem cells, and that targeting CD44 with Adapalene may significantly enhance therapy results and defer the onset of drug resistance in breast cancer patients.
Indexed as
Identifiers
42397497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.